Why the study?
Is intravenous ferric carboxymaltose cost-effective compared to placebo in iron-deficient patients with chronic heart failure in Sweden?
Population
Iron-deficient patients with chronic heart failure
Comparison
Intravenous ferric carboxymaltose (FCM) vs Placebo
Design
Other
Follow-up
24 weeks
Authors
Loading...
May support FCM adoption in Swedish iron-deficient HF; extends trial data via modeling but leaves real-world generalizability open.
Is intravenous ferric carboxymaltose cost-effective compared to placebo in iron-deficient patients with chronic heart failure in Sweden?
Intravenous ferric carboxymaltose is a cost-effective treatment for iron deficiency in chronic heart failure from a Swedish healthcare perspective, driven by increased health-related quality of life and fewer hospitalizations.
Hofmarcher et al. (2015) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: